Pluristem Therapeutics Inc. (PSTI)

3.79
NASDAQ : Health Technology
Prev Close 3.79
Day Low/High 3.73 / 3.96
52 Wk Low/High 3.24 / 13.80
Avg Volume 301.20K
Exchange NASDAQ
Shares Outstanding 15.31M
Market Cap 58.03M
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Pluristem To Participate In Three European Life Sciences Conferences In November

Pluristem To Participate In Three European Life Sciences Conferences In November

BioEurope 2015, EU Advanced Therapies Investor Day & Berlin Dialogue

Pluristem CEO Zami Aberman Elected To Board Of Directors Of The Alliance For Regenerative Medicine

Pluristem CEO Zami Aberman Elected To Board Of Directors Of The Alliance For Regenerative Medicine

ARM is the Preeminent Global Advocate for the Advancement of Regenerative Medicine

Pluristem And NIAID Met With U.S. FDA And Agreed On Development Plan For Initiation Of Pivotal Study Of PLX-R18 In The Treatment Of Acute Radiation Syndrome

Pluristem And NIAID Met With U.S. FDA And Agreed On Development Plan For Initiation Of Pivotal Study Of PLX-R18 In The Treatment Of Acute Radiation Syndrome

PLX-R18 for Use in Acute Radiation Syndrome (ARS) is Being Developed Under the Animal Rule Regulatory Pathway With the NIAID's Support

Pluristem President Yaky Yanay Elected As Co-Chairman Of Israel Advanced Technology Industries

Pluristem President Yaky Yanay Elected As Co-Chairman Of Israel Advanced Technology Industries

IATI Is the Largest Umbrella Organization for Israel's High Tech and Life Science Industries

Pluristem Granted U.S. Patent For Production Methods And Use Of Placental Cell Therapy In A Range Of Indications

Pluristem Granted U.S. Patent For Production Methods And Use Of Placental Cell Therapy In A Range Of Indications

Addresses Indications Including Peripheral Artery Disease for Which PLX Cells are Currently in Clinical Trials; Reinforces Company's Leadership Position in Large-Scale Manufacturing of Cell Therapies

Japan Grants Safety Clearance To Pluristem's PLX-PAD Cells For Use In Clinical Trials

Japan Grants Safety Clearance To Pluristem's PLX-PAD Cells For Use In Clinical Trials

Safety Clearance is Another Step Towards the Start of Phase II CLI Trial Via Japan's Accelerated Approval Pathway

Pluristem In Key Discussions With Europe's Adaptive Pathways Group On Phase II Protocol In Critical Limb Ischemia

Pluristem In Key Discussions With Europe's Adaptive Pathways Group On Phase II Protocol In Critical Limb Ischemia

Pluristem Also Presented Plans to Develop Accelerated Clinical Programs for PLX Cells in Ischemic Stroke, Muscle Wasting and Hip Fracture

Four Stem-Cell Stocks With Promise

Four Stem-Cell Stocks With Promise

Raymond James analyst Reni Benjamin says positive news may be ahead for these companies.

Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst

Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst

Fate Therapeutics (FATE) is developing several small molecules which modulate umbilical cord stem cells.

New Data Show Pluristem's PLX Cells Regulate The Immune System

New Data Show Pluristem's PLX Cells Regulate The Immune System

Study Results Published in Peer-Reviewed Scientific Journal

Pluristem Granted Australian Patent For 3D Cell Expansion Technology & Use Of PLX Cells In Broad Range Of Indications

Pluristem Granted Australian Patent For 3D Cell Expansion Technology & Use Of PLX Cells In Broad Range Of Indications

Phase I Trial of PLX-PAD Cells Underway in Australia for Pulmonary Arterial Hypertension

Pluristem Granted Key Cell Patents In Asia, Russia, Mexico, And Israel

Pluristem Granted Key Cell Patents In Asia, Russia, Mexico, And Israel

Company Fortifies IP Assets in Important Markets

Significant Progress For Pluristem: PLX Cells Were Selected For European Medicines Agency's Adaptive Pathways Pilot Project

Significant Progress For Pluristem: PLX Cells Were Selected For European Medicines Agency's Adaptive Pathways Pilot Project

Pluristem is Targeting Critical Limb Ischemia as the First Indication for Initial Marketing Authorization, Potentially Substantially Shortening the Time to Market of PLX Cells Via the Adaptive Pathways

Pluristem's PLX Cells One Step Closer To Entering Japan's Accelerated Pathway For Regenerative Medicine

Pluristem's PLX Cells One Step Closer To Entering Japan's Accelerated Pathway For Regenerative Medicine

Pluristem Completes Successful Meeting With PMDA and Satisfies Critical Prerequisite for Initiation of Clinical Study Targeting Fast-Track Approval in Japan

Pluristem Granted European Patent For Use Of Cells To Help Treat Damaged Bone Marrow

Pluristem Granted European Patent For Use Of Cells To Help Treat Damaged Bone Marrow

Patent Also Addresses Pluristem's Three Dimensional Culturing Technology

Pluristem's Clinical Advisory Board Prepares Phase II Clinical Trials In Critical Limb Ischemia In Europe And Japan

Pluristem's Clinical Advisory Board Prepares Phase II Clinical Trials In Critical Limb Ischemia In Europe And Japan

Company Targeting Accelerated Regulatory Pathways to Reduce PLX-PAD's Time to Market

TheStreet Quant Rating: D- (Sell)